between 1978 and 1981 , 463 evaluable postmenopausal patients 65 years of age or younger with operable breast cancer and metastases in axillary lymph nodes were entered in ludwig breast cancer study iii ( ludwig iii ) and randomly allocated to receive chemoendocrine therapy with cyclophosphamide , methotrexate , 5-fluorouracil , low-dose continuous prednisone , and tamoxifen ( cmfp + t ) for 12 monthly cycles , or endocrine therapy alone with prednisone and tamoxifen ( p + t ) for 1 year , or no adjuvant treatment after mastectomy ( observation ) .
C0025677
methotrexate
C0055985
cmfp